Coronary/Structural Heart

EndoWays LTD, Developer of the First Disposable Robot for the Cathlab, Acquired by Ascendum

OR YEHUDA, Israel, Feb. 8, 2021 /PRNewswire/ — EndoWays, developer of a disposable robotic system for the cathlab, today announced the completion of an acquisition of a majority of its shares by Ascendum at an undisclosed cash amount. EndoWays, which was founded in 2018 by Noam Shamay, Tovy Sivan and Tamir Ben David, is a portfolio company of MEDX […]

BioVentrix Receives 2021 NUB Status 1 Reimbursement Renewal in Germany for the Revivent TC TransCatheter Ventricular Enhancement System

SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter based Ventricular Restoration (TCVR), today announced that the German Institute for Hospital Remuneration (InEK) has renewed the NUB Status 1 reimbursement designation in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement […]

Neovasc Comments on Journal of the American Heart Association Publication

VANCOUVER and MINNEAPOLIS, Feb. 05, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Journal of the American Heart Association has published an article entitled, “Angina Severity, Mortality, and Healthcare Utilization Among Veterans with Stable Angina”. The prestigious journal is the official publication of […]

DAXOR CORPORATION AWARDED GRANT FROM THE CENTER FOR ADVANCING POINT OF CARE TECHNOLOGIES (CAPCAT) TO DEVELOP A POINT-OF-CARE BLOOD VOLUME ANALYZER

NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the Center for Advancing Point of Care Technologies (CAPCaT), a program run by the Massachusetts Medical Device Development Center […]

CHF Solutions Submits Patent Application for New and Improved Diagnostic Parameters to Support Hemodynamic Stability

EDEN PRAIRIE, Minn., Feb. 03, 2021 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the submission of a patent application to increase monitoring capabilities with its Aquadex SmartFlow™ system. The new technology is intended […]

STS 2021 presents results of a large clinical study showing 79% survival with Impella 5.5 with SmartAssist

Danvers, Mass .- ( BUSINESS WIRE ) -Abiomed (NASDAQ: ABMD) is a large target of 356 patients treated with Impella 5.5 with SmartAssist at 16 facilities in the United States and Germany. A large study announced that the survival rate at withdrawal from support was 79%. The majority of surviving patients recovered autologous heart function and did not require additional mechanical […]

Cardiovascular Systems, Inc. Announces Partnership With Chansu Vascular Techologies, LLC to Develop New Drug-Coated Balloon Technology

ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) announced today that it has partnered with Chansu Vascular Technologies, LLC (CVT) to develop novel peripheral and coronary everolimus drug-coated balloons (DCBs). This partnership brings together CSI’s leadership in the treatment of calcified arterial lesions with Dr. Philippe Marco, a pioneer […]

Neovasc Announces 2021 Renewal of German Reimbursement NUB Status 1 Designation for Neovasc Reducer for Treatment of Refractory Angina

VANCOUVER and MINNEAPOLIS, MN, Feb. 02, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc,  Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the German Institute for the Hospital Remuneration System(“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation once […]

BioCardia Update on Cell Therapy Product Development and 2021 Milestones

SAN CARLOS, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today provides an update on its cell therapy product development and 2021 milestones. BCDA-01, our CardiAMP autologous cell therapy under Phase III clinical development for the treatment of […]

Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years

AUSTIN, Texas, Jan. 31, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE clinical trial that demonstrate Edwards’ bioprosthetic surgical aortic valve with the company’s novel RESILIA tissue platform show favorable safety and hemodynamic performance through a median of five years follow-up. The data were presented at the […]